Nephrotic syndrome (NS) is associated with an increased risk of thromboembolic complications and activation of inflammatory and profibrotic pathways. In this prospective observational study, 67 adults with biopsy-proven primary glomerulonephritis and newly diagnosed NS received either warfarin (n=33) or apixaban (n=34) for thromboprophylaxis and were followed for six months. No thromboembolic events occurred in either group, demonstrating effective thromboprophylaxis with both agents.
However, bleeding events were significantly more frequent with warfarin than apixaban (33.3% vs 8.7%; OR 5.17; p=0.021), although all were minor. Both treatments reduced inflammatory and profibrotic activity, but apixaban produced earlier and greater declines in IL-6, TNF-Ξ±, TGF-Ξ²β, and urinary thrombin levels. Patients receiving apixaban also experienced a greater reduction in proteinuria and a lessβ¦
